Do You Have 'Ghost Poops'? Here's What That Says About Your Health.
Ghost poops are bowel movements that leave no skid marks in the toilet bowl or streaks on your toilet paper. Julia Barten, a physical therapist at the Stanford Pelvic Health Center, calls these 'unicorn poops' or 'no wipers.'
Why? 'Because the stool is so well formed that there's no remnant fecal matter left behind when you wipe,' she said.
In other words: They're the perfect poo. Here's what causes ghost poops — and what they say about your overall health:
If you take a look at the Bristol Stool Scale, a visual chart that classifies bowel movements, ghost poops qualify as a Type 4 poo, Barten said. Though there may be no evidence left in the pot, your poop might look like a piece of sausage that's smooth and soft. 'I would consider that to be an absolutely perfect poop,' Barten said.
Dr. Ira Leeds, a Yale Medicine colorectal surgeon, said ghost poops — or nirvana poops, as he calls them — easily (but noticeably) pass through the anal canal, sink to the bottom of the toilet, and leave no residue when wiping. These three factors are indicative of good bowel health.
A bowel movement that easily moves through the anal canal typically has an ideal consistency, according to Leeds. As such, you don't have to push as hard. This, in turn, minimizes straining and toilet time, which can both lead to complications like hemorrhoids and anal fissures, he explained.
Floating poops typically have a higher fat content, which causes them to stay on the surface of the water. But when your poop sinks? This suggests your digestion is functioning well.
'Fats, proteins and carbohydrates are being broken down properly into their constitutive parts that can be used by the body effectively,' Leeds said.
Finally, seeing a lot of residue on the toilet paper when wiping could mean you have an underlying health issue. According to Leeds, if you have to wipe at least three times, you may want to investigate. While your diet may be to blame (more on that below), excess wiping can occur if you have hemorrhoids, fissures, chronic itching, or an anal fistulae, Leeds noted.
There are multiple factors that can impact the consistency of your poop such as diet, your stress levels along with how much you sleep and exercise.
If you want to improve your gut health, Barten recommended starting with dietary changes. In general, a high-fiber diet will bulk up your stool so that it looks like the Type 4 poo on that Bristol Stool Scale. Aim to consume 25 to 30 grams of fiber a day, according to the Centers for Disease Control and Prevention. The more fiber you eat, the better your stool consistency will be, the easier it'll be to go to the bathroom, and the less toilet paper you'll need, Leeds said.
Many people have food sensitivities and intolerances. So, it's worth being aware of how you react to various foods and drinks. The reason: 'Avoiding foods that irritate your gut is important for having well-formed stools,' Barten said.
Evidence also shows that exercise can improve your bowel movements. 'Regular cardiovascular exercise improves nervous system regulation and movement literally helps things move better — our joints, our muscles and our bowels,' Barten said. The CDC suggests getting 150 minutes of exercise each week, but even small bursts of activity, like going on a short stroll, can boost your gut health.
Finally, prioritize your sleep (aim for seven to eight hours of shut-eye each night) and do your best to manage your stress. 'Our gut is our emotional center,' Barten said.
There's a strong mind-gut connection that significantly impacts gut motility. Barten's advice? Don't skimp out on self-care. Carve out some time, every day if you can, to relax and do the things you love. 'It's essential to achieve satisfying bowel movements,' she said.
If Your Poop Looks Like This, It's Time To See A Doctor
TikTok Claims Pooping With Your Hair Down Can Cause Breakouts. Is It True?
8 'Gross' Things Your Body Does That Are Actually Good For You
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
4 hours ago
- Boston Globe
First pill for postpartum depression shows varied real-world results
'I felt like I wasn't doing enough, I wasn't doing anything right,' she said. She began to think her son and husband might be better off without her. When the baby was about 5 months old, she tried to take her life with a gun. Cohn, 30, who lives near Fayetteville, North Carolina, was hospitalized for weeks and underwent surgeries to repair damage to her jaw, nose, tongue and face. But her postpartum depression remained challenging to treat. The hospital's maternal mental health specialists decided to have her try a medication that had recently become available: the first pill specifically for postpartum depression. Clinical trials had found that the drug, zuranolone, marketed as Zurzuvae and taken daily for 14 days, can ease symptoms for some women in as little as three days, while general antidepressants can take weeks. For Cohn, its impact was swift and striking. On her fourth day of taking it, she said she suddenly 'felt so much clarity in my head, like I didn't have nagging thoughts about not being good enough.' Advertisement Now, a year and a half after the drug became available, thousands of women have tried it, and their experiences have run the gamut. For some, symptoms improved remarkably. Others described a modest benefit that didn't last or said their depression persisted. And others didn't complete the two-week regimen because profound drowsiness, a common side effect of the drug, interfered with their ability to care for their babies or to fulfill other responsibilities. Advertisement One in eight women in the United States experiences depression during pregnancy or in the year after giving birth, the Centers for Disease Control and Prevention estimates, and effective treatments are crucially needed. While the fast-acting pill shows promise, doctors say the challenge now is to determine which patients will benefit and why some don't. Clinical trials of the drug found that postpartum depression improved in about 60% of patients. 'It's not everyone,' Dr. Samantha Meltzer-Brody, a leader of the trials and director of the Center for Women's Mood Disorders at the University of North Carolina at Chapel Hill, said at a National Institutes of Health conference. 'So, what is it about the people that are going to respond versus those that don't?' Stacey, 42, of San Diego, who asked to be identified only by her first name to protect her privacy, said Zurzuvae made her 'so tired' that after several days of taking it, 'I just felt like a zombie.' 'I actually felt more depressed while I was on it,' she said. To address Stacey's response to the medication, Dr. Alison Reminick, director of women's reproductive mental health at the University of California, San Diego, advised her to take half doses for the rest of the 14 days. But Stacey said she stopped Zurzuvae altogether, halfway through the regimen, because the sluggishness made it difficult to care for her baby. Advertisement 'The medication is incredibly sedating,' Reminick said. 'There's a warning on the box. They can't drive for 12 hours after taking it, and they can't really take care of their children without help.' Yet, some patients don't experience sedation and others welcome it because it helps them get much-needed sleep and feel less overwhelmed, said doctors who prescribe Zurzuvae. The week after Cohn started taking Zurzuvae, the turnaround of her symptoms was so obvious that she was discharged from the hospital. 'She had a really nice improvement of her postpartum depression with that medicine,' said Dr. Riah Patterson, a psychiatrist at the University of North Carolina Chapel Hill. Cohn finished the 14-day regimen at home and attended intensive outpatient therapy for months. Now, she has gone back to work as a tattoo artist, and she said that with weekly therapy and an anxiety medication, she is managing the aftermath of the crisis, including undergoing additional surgeries. 'I'm just excited to get a little bit closer to really being me again,' she said. She no longer feels anxious about her parenting ability and enjoys playing with her son and taking him to places like the local children's museum. 'He makes everything worth pushing through.' An ultrasound of Samantha Cohn's pregnancy on her refrigerator, near Fayetteville. The drug zuranolone relieved Cohn's postpartum depression, which was so severe that she tried to take her own life. MADELINE GRAY/NYT Importance of Quick Intervention Zurzuvae is a synthetic version of a steroid called allopregnanolone that originates in the brain. The theory behind the medication is that perinatal depression often arises as hormones that surge in pregnancy plummet during childbirth. Some patients seem particularly sensitive to that sudden drop-off, which also lowers levels of the steroid, Meltzer-Brody said. Zurzuvae can be taken with other antidepressants, and, since it is prescribed for only a single 14-day course, some doctors use it as an adjunct or bridge to ease severe symptoms before longer-term use of antidepressants. Advertisement Some patients who are breastfeeding have declined to take the drug because its penetration of breast milk has not yet been studied. Doctors said it is most likely safe, but if patients are concerned, they might pump two weeks' worth of milk before starting Zurzuvae. Initial logistical hurdles in obtaining Zurzuvae frustrated doctors who said the delays undermined the purpose of a quick-acting medication. Some insurers initially set strict conditions for covering the drug, which has a list price of $15,900. Doctors said some insurers required patients to try other antidepressants first or to obtain prescriptions from psychiatrists, steps that went beyond the FDA requirements for Zurzuvae. Joy Burkhard, CEO of the Policy Center for Maternal Mental Health, said most insurers and Medicaid no longer have such barriers, but a few still require extra steps. Zurzuvae is not available in retail pharmacies, only specialty pharmacies that require patients to take various measures to validate insurance and delivery information, according to a spokesperson for Chris Benecchi, chief operating officer of Sage, which is expected to be acquired by Supernus Pharmaceuticals later this year, said Sage had worked to resolve logistical issues and that prescriptions had increased. More than 10,000 orders have been sent to patients, Sage said, adding that about 80% of the prescriptions were issued by OB-GYNs. 'The majority of patients are able to get the medication within days,' Benecchi said, adding that if patients encounter delays, Sage will ship Zurzuvae directly 'as rapidly as possible.' Advertisement Quick access is crucial, doctors say. Hannah Ginther was hospitalized for a week last summer at UNC Chapel Hill for symptoms that included obsessively worrying that her second child, then 10 months old, had a neurological disorder, even though doctors said the baby did not. 'I just couldn't get out of that loop of jumping to worst-case-scenario,' Ginther, 36, said at her home in Wilmington, North Carolina. 'I would throw up. I struggled to get out of bed, struggled to do basic, daily-living things.' When she was discharged from the hospital, doctors prescribed Zurzuvae, but her insurance rejected coverage, saying she would qualify only if she had developed postpartum depression in her last trimester of pregnancy, or within four weeks after childbirth, Patterson said. Ultimately, the hospital appealed to Sage, which sent the drug to Ginther at no cost. But the insurance hiccups had caused a two-week delay, during which, Ginther said, her symptoms 'spiraled again.' She was rehospitalized for nine days. Dr. Julia Riddle, a psychiatrist at UNC Chapel Hill, said the second hospitalization might have been avoided if the Zurzuvae had arrived sooner. In clinical trials, patients helped by Zurzuvae continued doing well 45 days later. About half of those who took Zurzuvae were considered to be in remission. Riddle is following patients to see if the benefit can last longer. 'No one's illness is exactly the same,' Riddle said. So far 'no one has said they'd never take it again; it's just varying levels of how helpful it was.' Advertisement This article originally appeared in .
Miami Herald
5 hours ago
- Miami Herald
Covid-19 drug company liquidates assets in Chapter 11 bankruptcy
When the Covid-19 public health crisis began in the U.S. with the first confirmed case of the 2019 Novel Coronavirus in Washington state on Jan. 20, 2020, the terrifying pandemic was underway, and the Centers for Disease Control and Prevention would report its first confirmed death from the virus on Feb. 29. By March 3, 2020, CDC reported 60 confirmed cases in 12 states. On March 13, the first Trump administration declared a national emergency, and states started implementing shutdowns on March 15, according to the CDC's timeline of Covid-19 events. Don't miss the move: Subscribe to TheStreet's free daily newsletter Biotechnology firms Pfizer-BioTech and Moderna Therapeutics began developing Covid-19 vaccines in March 2020, and by November 2020, each company's Covid-19 vaccine would be found 95% effective in clinical trials. Related: CVS rival pharmacy chain files for Chapter 11 bankruptcy Another biotech firm, Regeneron, in November received approval of an antibody treatment to significantly reduce virus levels within days. In December 2020, Covid-19 vaccinations began, and by Dec. 24, 1 million people had been vaccinated in the U.S. CDC said that by June 1, 2022, the U.S. reported over 84 million Covid-19 infections and over 1 million deaths. About a year later, Pfizer reported on its website that on May 5, 2023, the World Health Organization declared an end to the Covid-19 public health emergency, while the U.S. Department of Health & Human Services did the same on May 11, 2023. The healthcare industry's response to the Covid-19 pandemic was so effective that beginning on May 1, 2024, hospitals were no longer required to report Covid-19 hospital admissions, hospital capacity, or hospital occupancy data to the U.S. Department of Health & Human Services through the Centers for Disease Control and Prevention's National Healthcare Safety Network, according to the CDC website. The end of the crisis also ended the need for massive amounts of Covid-19 drugs. With the Covid-19 pandemic subsiding, companies that stepped forward to develop vaccines, drugs, and treatments during the crisis are now facing declining demand for their services to develop Covid-19 products. With no dire need for Covid-19 products, some drug companies have been forced to downsize or even shut down operations because of a lack of business opportunities. Essential drug manufacturer Aluchua Government Services Inc., which developed Covid-19 therapy drugs under U.S. government contracts, has filed for Chapter 11 bankruptcy with plans to wind down operations and sell its assets. Related: Giant healthcare company files Chapter 11 bankruptcy seeking sale The Aluchua, Fla.-based pharmaceutical company filed its petition in the U.S Bankruptcy Court for the District of Delaware, listing $50 million in assets and $100 million to $500 million in liabilities. The debtor's largest creditors include United States International Development Finance Corp., owed $246 million; Defense Contract Management Agency, owed $11.95 million; and Sigma-Aldrich Inc. $1.33 million. Aluchua was founded in 1999 to develop new drugs and to increase efficacy of existing ones. In 2013, it was awarded a greenfield contract with the U.S. Department of Defense, and in February 2020, it was awarded a contract to develop an advanced monoclonal antibody therapy against Covid-19 infection. The Covid-19 drug was one of several that the debtor partnered with the U.S. government to develop and produce drugs, vaccines, and treatments. The debtor needed to file for Chapter 11 protection after demand for its services began to decline in late 2023 and certain government contracts were wound down or scaled back, according to Aluchua's Chief Restructuring Officer Janet R. Naifeh of FTI Consulting Inc. Aluchua's efforts to replace its government business with commercial contracts failed, which forced it to scale down production and lay off 125 employees from January through April 2025. It reduced its staff by another 67 employees on June 20 and July 1, which, combined with the earlier layoffs, amounted to termination of 80% of its workforce. The company employed 13 full-time and three temporary workers as of the petition date. The company marketed itself for sale beginning in February 2025, but was unable to complete a transaction and decided its only viable option was to file for Chapter 11 bankruptcy, wind down its business, and sell its assets. Related: Iconic retail chain closing its remaining stores in bankruptcy The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
5 hours ago
- Yahoo
Summer Covid cases are rising across the U.S. — Is it time for a vaccine?
As Covid cases begin to rise this summer, many may be wondering: What are my risks, and is it time to get another vaccine? As of July 15, Covid cases were growing or likely growing in 27 states including Texas, Illinois, Kentucky, Virginia and Ohio, according to the Centers for Disease Control and Prevention. Rates of positive Covid tests have also been increasing in recent weeks, the CDC says, specifically in the southern region of the country. N.B.1.8.1 is the current dominant variant in the United States, accounting for 43% of all new Covid cases, according to the CDC. It's an offshoot of the XVD.1.5.1 strain, a descendant of the omicron variant. N.B.1.8.1 was responsible for a surge in hospitalizations in China earlier this year. It's been nicknamed 'razor blade throat,' as there have been anecdotal reports of some people getting painful sore throats, said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center in Nashville, Tennessee. Schaffner noted, however, that sore throats have been a common symptom of Covid since it first began spreading. 'I doubt the clinical spectrum of Covid has changed substantially,' Schaffner said. Do I need a Covid booster? When will the new vaccines be available? The uptick in cases comes as many Americans have likely gone a year or longer without a Covid shot. In May, the Food and Drug Administration asked drugmakers to update their Covid vaccines to target the LP.8.1 strain, a descendent of JN.1, which began spreading widely in 2023 and is another offshoot of omicron. LP.8.1 currently accounts for 31% of all new cases, per the CDC. The new shots won't be available until the fall, and are expected to be approved only for adults 65 and up and kids and adults with at least one medical condition that puts them at risk of severe illness. Healthy kids and adults who want a shot may have to find an older version or pay out of pocket. A single dose can cost as much as $140. Experts say, however, that population immunity — whether from vaccination, prior infection or both — may shield much of the public for now. 'While we don't have a lot of high level of immunity in the population right now, because it's been so long, we may have enough low level immunity to just make it a little bit harder for that virus to transmit easily from person to person,' said Andy Pekosz, an infectious disease researcher at Johns Hopkins University. Indeed, weekly hospitalization rates have remained low, suggesting that the new variant may not be leading to severe illness. The number of cases are still drastically lower than those this time last year, when the test positivity rate peaked in August at 17.9%. The 2025 season has yet to scrape 5%. Pekosz said it isn't unusual for cases to rise during the summer time, when people are likely to crowd indoors to escape the heat. However, he believes that if there is a summer surge of cases, it will be a small one. 'The variants have been around for a while and haven't caused any major surges up until date,' Pekosz said. 'So again, I'm hopeful that if we see a surge, it'll be a low level surge compared to previous years.' Dr. Ofer Levy, director of the precision vaccines program at Boston Children's Hospital, who has advised the FDA, said people who are at high risk of severe illness still may want to consider getting a Covid shot, if they can find one. High risk groups include: Older adults People with weakened immune systems Pregnant women Those with underlying health conditions, such as asthma and heart disease Getting a shot is especially important, Levy said, for those who haven't had one in over a year and whose immunity has likely waned. 'If you're in a high risk group and you're in a state where cases are rising, you may want to just get the first available appointment and get a shot to protect yourself,' he said. People at high risk can then consider getting an additional Covid shot when the updated vaccines are distributed in the fall, he said. Covid has two waves a year Schaffner, of Vanderbilt, said people in the high risk groups may also want to consider wearing a mask during indoor activities, such as the movies. Healthy adults and children may be able to wait longer before getting another shot, Levy added. 'If you're in a lower risk group, that's where things get fuzzy,' he said. 'I mean if you want a vaccine and your health care provider concurs and you can get it.' Dr. Michael Phillips, an infectious disease doctor at NYU Langone, said that he sees mostly immunocompromised and older adults test positive for the virus. For those who haven't gotten a Covid shot in years, Phillips said he doesn't think they should worry just yet. 'If you're younger, otherwise healthy, I think you're OK,' Phillips said. 'If you have underlying pulmonary disease, you know, if you're an older age group, now that's a time when you should be really talking to a doctor and saying, 'Gosh, should I be getting a booster for Covid?'' He said that the amount of positive Covid tests NYU Langone has seen has decreased 40% since February. Fatima Amaeka, a senior analyst at the Center for Outbreak Response Innovation at Johns Hopkins, said she expects the current wave to peak around September. Schaffner said to expect another wave in the late fall and winter. '[Covid] has two increases each year,' he said. 'Everyone is familiar with the winter increase that goes along with flu and RSV.' This article was originally published on Solve the daily Crossword
